Human Immunodeficiency Virus (HIV) Infections (AIDS) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

Powered by

All the vital news, analysis, and commentary curated by our industry experts.

$2500

The Human Immunodeficiency Virus Pipeline market research report provides a comprehensive overview on the therapeutics under development for Human Immunodeficiency Virus, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type.  The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.  Additionally, the report provides an overview of key players involved in therapeutic development for Human Immunodeficiency Virus and features dormant and discontinued projects.

Key Targets in the Human Immunodeficiency Virus Pipeline Drugs Market

In the HIV pipeline drugs market the key targets are Reverse Transcriptase, Surface Protein gp12, Gag, HIV 1 Integrase, Glycoprotein 41, T Cell Surface Glycoprotein CD4, HIV 1 Retropepsin, P27, Pol Polyprotein, Capsid Protein, and Glycoprotein 140.

Human Immunodeficiency Virus Pipeline Drugs Market, by Targets

Human Immunodeficiency Virus Pipeline Drugs Market, by Targets

For more target insights, download a free report sample

Key MoA in the Human Immunodeficiency Virus Pipeline Drugs Market

Reverse Transcriptase Inhibitor has the highest number of pipeline products followed by Surface Protein gp12 Inhibitor, HIV 1 Integrase Inhibitor, Glycoprotein 41 Inhibitor, T Cell Surface Glycoprotein CD4 Inhibitor, HIV 1 Retropepsin Inhibitor, Capsid Protein Inhibitor, HIV Integrase Inhibitor, C-C Chemokine Receptor Type 5 Antagonist, and Gag Inhibitor.

Human Immunodeficiency Virus Pipeline Drugs Market, by MoA

Human Immunodeficiency Virus Pipeline Drugs Market, by MoA

To get more insights on key MoA, download a free sample report

Human Immunodeficiency Virus Pipeline Drugs Market Segmentation by RoA

The key routes of administration in the HIV pipeline drugs market are Oral, Intramuscular, Intravenous, Subcutaneous, Parenteral, Topical, Vaginal, Intradermal, Rectal, and Nasal. Oral has the maximum number of pipeline products.

Human Immunodeficiency Virus Pipeline Drugs Market Analysis, by RoA

Human Immunodeficiency Virus Pipeline Drugs Market Analysis, by RoA

To get more insights on key RoA, download a free sample report

Key Molecule Types in the Human Immunodeficiency Virus Pipeline Drugs Market

The key molecule types in the HIV pipeline drugs market are Small Molecule, Monoclonal Antibody, Subunit Vaccine, Recombinant Vector Vaccine, Gene-Modified Cell Therapy, Synthetic Peptide, DNA Vaccine, Vaccine, Cell Therapy, and mRNA Vaccine.

Human Immunodeficiency Virus Pipeline Drugs Market, by Molecule Type

Human Immunodeficiency Virus Pipeline Drugs Market, by Molecule Type

To get more insights on key molecule types, download a free sample report

Major Companies in the Human Immunodeficiency Virus Pipeline Drugs Market

The major companies in the HIV pipeline drugs market are Gilead Sciences Inc, ViiV Healthcare UK Ltd, Merck & Co Inc, Viriom Inc, Aphios Corp, Enochian Biosciences Inc, Statera Biopharma Inc, Johnson & Johnson, OyaGen Inc, and TaiMed Biologics Inc.

Human Immunodeficiency Virus Pipeline Drugs Market, by Major Companies

Human Immunodeficiency Virus Pipeline Drugs Market, by Major Companies

For more company insights, download a free sample report

Human Immunodeficiency Virus Pipeline Drugs Market Overview

Key Targets Reverse Transcriptase, Surface Protein gp12, Gag, HIV 1 Integrase, Glycoprotein 41, T Cell Surface Glycoprotein CD4, HIV 1 Retropepsin, P27, Pol Polyprotein, Capsid Protein, and Glycoprotein 140
Key Mechanisms of action Reverse Transcriptase Inhibitor, Surface Protein gp12 Inhibitor, HIV 1 Integrase Inhibitor, Glycoprotein 41 Inhibitor, T Cell Surface Glycoprotein CD4 Inhibitor, HIV 1 Retropepsin Inhibitor, Capsid Protein Inhibitor, HIV Integrase Inhibitor, C-C Chemokine Receptor Type 5 Antagonist, and Gag Inhibitor
Key Routes of Administration Oral, Intramuscular, Intravenous, Subcutaneous, Parenteral, Topical, Vaginal, Intradermal, Rectal, and Nasal
Key molecule types Small Molecule, Monoclonal Antibody, Subunit Vaccine, Recombinant Vector Vaccine, Gene-Modified Cell Therapy, Synthetic Peptide, DNA Vaccine, Vaccine, Cell Therapy, and mRNA Vaccine
Major companies Gilead Sciences Inc, ViiV Healthcare UK Ltd, Merck & Co Inc, Viriom Inc, Aphios Corp, Enochian Biosciences Inc, Statera Biopharma Inc, Johnson & Johnson, OyaGen Inc, and TaiMed Biologics Inc

Scope

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Human Immunodeficiency Virus
  • The pipeline guide reviews pipeline therapeutics for Human Immunodeficiency Virus by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Human Immunodeficiency Virus therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Human Immunodeficiency Virus therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA), and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews the latest news related to pipeline therapeutics for Human Immunodeficiency Virus

Reasons to Buy

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with a potentially strong product portfolio and create effective countercstrategies to gain a competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Human Immunodeficiency Virus
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and their most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Human Immunodeficiency Virus pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from the pipeline.

2A Pharma AB
AbbVie Inc
Abivax SA
Acceleromics SL
Actinobac Biomed Inc
Adare Pharma Solutions
Advanced Gene and Cell Technologies
Aelix Therapeutics SL
AiCuris Anti-infective Cures AG
AIM ImmunoTech Inc
AlbaJuna Therapeutics
Alphamab Oncology
AlphaVax Inc
American Gene Technologies International Inc
Amgen Inc
Antion Biosciences SA
Aphios Corp
Apimeds Inc
Ascletis Pharma Inc
AUM LifeTech Inc
Auro Vaccines LLC
Autonomous Therapeutics Inc
Avixgen Inc
B Cell Design SAS
Bionor Holding AS
BioNTech SE
Biosantech SA
Biotron Ltd
Bolder Biotechnology Inc
Brandenburg Antiinfektiva GmbH
Brii Biosciences Ltd
Bristol-Myers Squibb Co
BryoLogyx Inc
Bukwang Pharmaceutical Co Ltd
Celdara Medical LLC
Celldex Therapeutics Inc
Centivax Inc
Chiesi Farmaceutici SpA
Cidara Therapeutics Inc
Clover Biopharmaceuticals Ltd
Cocrystal Pharma Inc
Codiak BioSciences Inc
Collaborations Pharmaceuticals Inc
Consegna Pharma Inc
ConserV Bioscience Ltd
CSL Ltd
Curevac NV
Cytodyn Inc
CytRx Corp
Dewpoint Therapeutics Inc
DFH Pharma Inc
Diaccurate
E-Vaccines Inc
Emmune Inc
Enochian Biosciences Inc
Enzo Biochem Inc
Enzolytics Inc
EpitoGenesis Inc
EpiVax Inc
eTheRNA Immunotherapies NV
Evotec SE
Exavir Therapeutics Inc
Excision BioTherapeutics Inc
ExQor Technologies Inc
Fox Chase Chemical Diversity Center Inc
Frontier Biotechnologies Inc
FUJIFILM Toyama Chemical Co Ltd
GB Sciences Inc
GeneCure Biotechnologies LLC
Genetic Immunity Inc
GeoVax Labs Inc
Gilead Sciences Inc
Globeimmune Inc
Greffex Inc
Gritstone Bio Inc
GT Biopharma Inc
Guangzhou Bio-gene Technology Co Ltd
HDT Bio Corp
Helocyte Biosciences Inc
Hepion Pharmaceuticals Inc
Hetero Drugs Ltd
Hoverink Biotechnologies Inc
ID Pharma Co Ltd
IGXBio Inc
Immune Modulation Inc
Immune Response BioPharma Inc
ImmunityBio Inc
Immuno Cure BioTech Ltd
Immunocore Limited
Immunologik GmbH
Indaptus Therapeutics Inc
Innovare R & D SA De CV
Inovio Pharmaceuticals Inc
Intarcia Therapeutics Inc
Intrucept Biomedicine LLC (Inactive)
InvVax Inc
ISR Immune System Regulation Holding AB
Ithax Pharmaceuticals Inc
Jericho Sciences LLC
Jiangsu Aidea Pharmaceutical Co Ltd
Jiangsu Hengrui Medicine Co Ltd
Johnson & Johnson
Kainos Medicine Inc
Kanglin Biotech Hangzhou Co Ltd
Karyopharm Therapeutics Inc
Lauren Sciences LLC
Legend Biotech Corp
Longevity Biotech Inc
Luckwel Pharmaceuticals Inc
Lyndra Therapeutics Inc.
MacroGenics Inc
Mapp Biopharmaceutical Inc
MarPam Pharma LLC
Merck & Co Inc
METiS Pharmaceuticals
Miltenyi Biotec BV & Co KG
Minka Therapeutics SA
Moderna Inc
Molecular Express Inc
Moleculin Biotech Inc
Mologen AG
Mutabilis SA
Mycenax Biotech Inc
Mymetics Corp
NanoViricides Inc
Navigen Inc
NeED Pharma srl
Neuraxpharm France SAS
New World Laboratories Inc
NovalGen Ltd
Novartis AG
Novodux
Omeros Corp
Oncotelic Inc
Oncovir Inc
OncXerna Therapeutics Inc
Oneness Biotech Co Ltd
Orion Biotechnology Canada Ltd
Osel Inc
OyaGen Inc
Palisades Therapeutics
Pepscan Therapeutics BV
Pharmasyntez
Pharmsynthez
Phoenix Biotechnology Inc
PlantForm Corp
Prosetta Biosciences Inc
Protheragen Inc
PROVIREX Genome Editing Therapies GmbH
Qura Therapeutics LLC
Recombio SL
ReiThera Srl
Repair Biotechnologies Inc
Replikins Ltd
Resverlogix Corp
RetroVirox Inc
Rodos BioTarget GmbH
Samjin Pharm Co Ltd
Sangamo Therapeutics Inc
Satellos Bioscience Inc
Savoy Pharmaceuticals Inc
Seagen Inc
Secura Bio Inc
Serum Institute of India Pvt Ltd
Shanghai De Novo Pharmatech Co Ltd
Shanghai Pharmaceutical Group Co Ltd
Shanghai Record Pharmaceuticals Co Ltd
Shanxi Kangbao Biological Product Co Ltd
Shenzhen Chipscreen Biosciences Co Ltd
Shionogi & Co Ltd
SignalRx Pharmaceuticals Inc
Sirga Advanced Biopharma Inc
ST Pharm Co Ltd
Staidson BioPharma Inc
Starpharma Holdings Ltd
Statera Biopharma Inc
Sumagen Co Ltd
Sunomix Therapeutics
Susavion Biosciences Inc
Taiga Biotechnologies Inc
TaiMed Biologics Inc
Takara Bio Inc
TechnoVax Inc
Tetranov International Inc
Tevogen Bio Inc
TheraJect Inc
Theratechnologies Inc
Theravectys SA
Transgene Biotek Ltd
Transposon Therapeutics Inc
TVAX Biomedical Inc
United Biomedical Inc
Uvax Bio LLC
Vault Pharma Inc
VG Life Sciences Inc
Vichem Chemie Research Ltd
viIMMUNE
ViiV Healthcare UK Ltd
Vir Biotechnology Inc
Viramatix Sdn Bhd
Viravaxx AG
Viriom Inc
ViroStatics SRL
Winsantor Inc
Wuhan Bio-Raid Biotechnology Co Ltd
Xi'An Yufan Biotechnology Co Ltd
Xyphos Biosciences Inc
Yaso Therapeutics Inc
Yisheng Biopharma Co Ltd
Zata Pharmaceuticals Inc
Zion Medical
Zydus Lifesciences Ltd

Table of Contents

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Human Immunodeficiency Virus (HIV) Infections (AIDS) – Overview

Human Immunodeficiency Virus (HIV) Infections (AIDS) – Therapeutics Development

Pipeline Overview

Pipeline by Companies

Pipeline by Universities/Institutes

Products under Development by Companies

Products under Development by Universities/Institutes

Human Immunodeficiency Virus (HIV) Infections (AIDS) – Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Human Immunodeficiency Virus (HIV) Infections (AIDS) – Companies Involved in Therapeutics Development

Human Immunodeficiency Virus (HIV) Infections (AIDS) – Drug Profiles

Human Immunodeficiency Virus (HIV) Infections (AIDS) – Dormant Projects

Human Immunodeficiency Virus (HIV) Infections (AIDS) – Discontinued Products

Human Immunodeficiency Virus (HIV) Infections (AIDS) – Product Development Milestones

Featured News & Press Releases

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

Table

List of Tables

Number of Products under Development for Human Immunodeficiency Virus (HIV) Infections (AIDS), 2022

Number of Products under Development by Companies, 2022

Number of Products under Development by Universities/Institutes, 2022

Products under Development by Companies, 2022

Products under Development by Universities/Institutes, 2022

Number of Products by Stage and Target, 2022

Number of Products by Stage and Mechanism of Action, 2022

Number of Products by Stage and Route of Administration, 2022

Number of Products by Stage and Molecule Type, 2022

Human Immunodeficiency Virus (HIV) Infections (AIDS) – Dormant Projects, 2022

Human Immunodeficiency Virus (HIV) Infections (AIDS) – Discontinued Products, 2022

Figures

List of Figures

Number of Products under Development for Human Immunodeficiency Virus (HIV) Infections (AIDS), 2022

Number of Products under Development by Companies, 2022

Number of Products under Development by Universities/Institutes, 2022

Number of Products by Top 10 Targets, 2022

Number of Products by Stage and Top 10 Targets, 2022

Number of Products by Top 10 Mechanism of Actions, 2022

Number of Products by Stage and Top 10 Mechanism of Actions, 2022

Number of Products by Top 10 Routes of Administration, 2022

Number of Products by Stage and Top 10 Routes of Administration, 2022

Number of Products by Top 10 Molecule Types, 2022

Number of Products by Stage and Top 10 Molecule Types, 2022

Frequently asked questions

Human Immunodeficiency Virus (HIV) Infections (AIDS) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update thematic reports
Currency USD
$2,500

Can be used by individual purchaser only

$7,500

Can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company


Undecided about purchasing this report?

Enquire Before Buying

Get in touch to find out about multi-purchase discounts

reportstore@globaldata.com
Tel +44 20 7947 2745

Every customer’s requirement is unique. With over 220,000 construction projects tracked, we can create a tailored dataset for you based on the types of projects you are looking for. Please get in touch with your specific requirements and we can send you a quote.

See what our customers are saying

“The GlobalData platform is our go-to tool for intelligence services. GlobalData provides an easy way to access comprehensive intelligence data around multiple sectors, which essentially makes it a one-for-all intelligence platform, for tendering and approaching customers.

GlobalData is very customer orientated, with a high degree of personalised services, which benefits everyday use. The highly detailed project intelligence and forecast reports can be utilised across multiple departments and workflow scopes, from operational to strategic level, and often support strategic decisions. GlobalData Analytics and visualisation solutions has contributed positively when preparing management presentations and strategic papers.”

Business Intelligence & Marketing Manager, SAL Heavy Lift

“COVID-19 has caused significant interference to our business and the COVID-19 intelligence from GlobalData has helped us reach better decisions around strategy. These two highlights have helped enormously to understand the projections into the future concerning our business units, we also utilise the project database to source new projects for Liebherr-Werk to use as an additional source to pitch for new business.”

Market Analyst & Management, Liebherr-Werk

Your daily news has saved me a lot of time and keeps me up-to-date with what is happening in the market, I like that you almost always have a link to the source origin. We also use your market data in our Strategic Business Process to support our business decisions. By having everything in one place on the Intelligence Center it has saved me a lot of time versus looking on different sources, the alert function also helps with this.

Head of Key Accounts, Saab AB

Having used several other market research companies, I find that GlobalData manages to provide that ‘difficult-to-get’ market data that others can’t, as well as very diverse and complete consumer surveys.

Marketing Intelligence Manager, Portugal Foods

Our experience with GlobalData has been very good, from the platform itself to the people. I find that the analysts and the account team have a high level of customer focus and responsiveness and therefore I can always rely on. The platform is more holistic than other providers. It is convenient and almost like a one stop shop. The pricing suite is highly competitive and value for our organisation.

I like reports that inform new segments such as the analysis on generation Z, millennials, the impact of COVID 19 to our banking customers and their new channel habits. Secondly the specialist insight on affluent sector significantly increases our understanding about this group of customers. The combination of those give us depth and breadth of the evolving market.

I’m in the business of answering and helping people make decisions so with the intelligence center I can do that, effectively and efficiently. I can share quickly key insights that answer and satisfy our country stakeholders by giving them many quality studies and primary research about competitive landscape beyond the outlook of our bank. It helps me be seen as an advisory partner and that makes a big difference. A big benefit of our subscription is that no one holds the whole data and because it allows so many people, so many different parts of our organisation have access, it enables all teams to have the same level of knowledge and decision support.

Head of Customer Insight and Research, Standard Chartered

“I know that I can always rely on Globaldata’s work when I’m searching for the right consumer and market insights. I use Globaldata insights to understand the changing market & consumer landscape and help create better taste & wellbeing solutions for our customers in food, beverage and healthcare industries.

Globaldata has the right data and the reports are of very high quality compared to your competitors. Globaldata not only has overall market sizes & consumer insights on food & beverages but also provides insights at the ingredient & flavour level. That is key for B2B companies like Givaudan. This way we understand our customers’ business and also gain insight to our unique industry”

Head of Consumer Sensory Insights, Givaudan

GlobalData provides a great range of information and reports on various sectors that is highly relevant, timely, easy to access and utilise.  The reports and data dashboards help engagement with clients; they provide valuable industry and market insights that can enrich client conversations and can help in the shaping of value propositions. Moreover, using GlobalData products has helped increase my knowledge of the finance sector, the players within it, and the general threats and opportunities.

I find the consumer surveys that are carried out to be extremely beneficial and not something I have seen anywhere else. They provided an insightful view of why and which consumers take (or don’t) particular financial products. This can help shape conversations with clients to ensure they make the right strategic decisions for their business.

One of the challenges I have found is that data in the payments space is often piecemeal. With GD all of the data I need is in one place, but it also comes with additional market reports that provide useful extra context and information. Having the ability to set-up alerts on relevant movements in the industry, be it competitors or customers, and have them emailed directly to me, ensures I get early sight of industry activity and don’t have to search for news.

Senior Account Manager, TSYS
Go even deeper with GlobalData Intelligence Center

Every Company Report we produce is powered by the GlobalData Intelligence Center.

Subscribing to our intelligence platform means you can monitor developments at Human Immunodeficiency Virus (HIV) Infections (AIDS) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update in real time.

  • Access a live Human Immunodeficiency Virus (HIV) Infections (AIDS) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update dashboard for 12 months, with up-to-the-minute insights.
  • Fuel your decision making with real-time deal coverage and media activity.
  • Turn insights on financials, deals, products and pipelines into powerful agents of commercial advantage.